Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment

Journal of Glaucoma

Volumn 6, Issue 4, 1997, Pages 250-258

  Greenfield, David S ^a,b   Liebmann, Jeffrey M ^a   Ritch, Robert ^a  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alpha2 adrenoreceptor agonist; Brimonidine

Indexed keywords

BETAXOLOL; BRIMONIDINE; TIMOLOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EYE DROPS; QUINOXALINE DERIVATIVE;

AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; ARGON LASER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; NONHUMAN; NORMAL HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; TOPICAL DRUG ADMINISTRATION; TRABECULOPLASTY; VISUAL IMPAIRMENT; DOSE RESPONSE; DRUG EFFECT; TRABECULECTOMY;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; BETAXOLOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; QUINOXALINES; TIMOLOL; TRABECULECTOMY;

EID: 0030611851     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. Arch Ophthalmol 1991;109:1090-5.
2. Thylefors B, Négrel AD. The global impact of glaucoma. Bull WHO 1994;72:323-6.
3. Novack GD, Robin AL, Derick RJ. New medical treatments for glaucoma. Int Ophthalmol Clin 1993;33:183-202.
4. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(suppl 1):9-18.
5. Makabe R. Ophthalmological studies with dichlorophenyl-aminoimidazoline. Dtsch Med Wochenschr 1966;91:1686.
6. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Gilman AG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1996:199-248.
7. Krieglstein GK, Gramer E. The response of ophthalmic arterial pressure to topically applied clonidine. Graefes Arch Clin Exp Ophthalmol 1978;207:1-5.
8. Hodapp E, Kolker, AE, Kass MA, al. The effect of topical clonidine on intraocular pressure. Arch Ophthalmol 1981;99:1208.
9. Rouot B, Leclerc G, Bieth N, et al. Pharmacological study of para-aminoclonidine, an alpha sympathomimetic. Coll R Acad Sci 1978;286:909-12.
10. Chandler ML, DeSantis L. Studies of p-aminoclonidine as a potential antiglaucoma agent. Invest Ophthalmol Vis Sci 1985;26 (suppl):227.
11. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995;102:456-61.
12. Brown RH, Stewart RH, Lynch MG, et al. ALO 2145 reduces the IOP elevation after anterior segment laser surgery. Ophthalmology 1988;95:378-84.
13. Holmwood PC, Chase RD, Krupin T, et al. Apraclonidine and argon laser trabeculoplasty. Am J Ophthalmol 1992;114:19-22.
14. Robin AL, Pollack IP, House B, Enger C. Effect of ALO-2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol 1987;105:646-50.
15. Robin AL, Pollack IP, DeFaller JM. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride,) on intraocular pressure rise following argon laser iridotomy. Arch Ophthalmol 1987;105:1208-11.
16. Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. Am J Ophthalmol 1992;113:401-5.
17. Robin AL, Ritch R, Shin DH, et al. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Am J Ophthalmol 1995;120:423-32.
18. Butler P, Mannschreck M, Lin S, et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113:293-6.
19. Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. Ophthalmology 1993;100:1318-23.
20. Stewart WC, Ritch R, Shin DH, et al. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol 1995;113:287-92.
21. Araujo SV, Bond JB, Wilson RP, et al. Long term effect of apraclonidine. Br J Ophthalmol 1995;79:1098-101.
22. Burke J, Padillo E, Shan T, et al. AGN 190342 (UK-14304-18) stimulates an imidazoline receptor to lower intraocular pressure (IOP) in conscious monkeys. Invest Ophthalmol Vis Sci 1991;32 (suppl):867.
23. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-7.
24. Gluchowski C, Jeon YT, Wetzel JM, et al. Use of recombinant human alpha adrenergic receptors for the pharmacological evaluation of alpha adrenergic ocular hypertensive agents. Invest Ophthalmol Vis Sci 1994;35(suppl):1399.
25. Langer SZ. Presynaptic receptors and the regulation of transmitter release in the peripheral and central nervous system. Sixth Gaddum Memorial Lecture. Br J Ophthalmol 1977;60:481-97.
26. 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 1989;240:1310-6.
27. 2-adrenergic receptors: structure, function and therapeutic implications. Reading, England: Harwood Academic, 1996:179-87.
28. Barnebey HS, Robin AL, Zimmerman TJ, et al. The efficacy of brimonidine in decreasing elevation in intraocular pressure after laser trabeculoplasty. Ophthalmology 1993;100:1083-8.
29. 2 agonist (UK-14304-18) in cats, rabbits, and monkeys. Curr Eye Res 1986;5:665-76.
30. Burke J, Crosson C, Potter DE. Can UK-14304-18 lower IOP in rabbits by a peripheral mechanism? Curr Eye Res 1989;8:547-52.
31. Angelov O, Wiese A, Tang-Liu D, et al. Preclinical safety profile of brimonidine. Eur J Ophthalmol 1996;6:21-5.
32. Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology on normal and sympathectomized monkeys. Exp Eye Res 1994;59:633-44.
33. Burke J, Kharlamb A, Shan T, et al. Adrenergic and imidazoline receptor-mediated responses to UK-14302-18 (brimonidine) in rabbits and monkeys: a species difference. In: Reis D, Bousquet P, Parini A, eds. The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine. New York: New York Academy of Science, 1995:78-95.
34. Kharlamb A, Shan T, Runde E, et al. The cynomolgus monkey has a CNS imidazoline receptor which mediates IOP and cardiovascular responses to UK-14304 (AGN 190342). Invest Ophthalmol Vis Sci 1992;33(suppl):1115.
35. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(suppl 1):27-37.
36. Serle JB, The brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol 1996;41(suppl 1):39-47.
37. Spada CS, Nieves AL, Burke JA, et al. Comparative effects of brimonidine, p-aminoclonidine and clonidine on arteriolar caliber in human retinal tissue. Invest Ophthalmol Vis Sci 1995;36(suppl): 1041.
38. Joyner WL, Gilmore JP. Tissues grafted into the cheek pouch of the hamster. In: Baker CH, Nastuk WL, eds. Microcirculatory Technology. Physical techniques in biology and medicine. London: Academic, 1986:3-17.
39. Joyner WL, Tang T, Macek BA, et al. Human ocular microcirculation: intravital microscopy of retinal and choroid circulations grafted into the cheek pouch of the hamster. In: Weinreb RN, Joyner WL, Wheeler LA, eds. Biology of the Ocular Microcirculation. Elsevier Scientific: Amsterdam, 1992:61-70.
40. Chien DS, Richman J, Zolezio H, et al. Drug distribution of brimonidine in albino and pigmented rabbit eyes. Pharm Res 1992; 9:336.
41. Acheampong AA, Shackleton M, Tang-Liu DDS. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Disposition 1995;27:708-12.
42. Angelov O, Wiese A, Tang-Liu D, et al. One year oral and one year ocular toxicity studies of AGN-190342-LF (brimonidine tartrate) in cynomolgus monkeys. Toxicologist 1994;14:255.
43. Derick RJ, Walters TR, Robin AL, et al. Brimonidine tartrate: a one-month dose response study. Invest Ophthalmol Vis Sci 1993; 34(suppl):929.
44. Robin AL, Barnebey HS, Choplin N, et al. Brimonidine tartrate dose-response study in glaucoma and ocular hypertension. Eur J Ophthalmol 1995;5(suppl):156.
45. Rosenthal AL, Walters T, Berg E, et al. A comparison of the safety and efficacy of brimonidine 0.2%, bid verses tid, in subjects with elevated intraocular pressure. Invest Ophthalmol Vis Sci 1996;37 (suppl):1102.
46. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77-83.
47. David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol 1993;111:1387-90.
48. Brimonidine-ALT Study Group. Effect of brimonidine 0.5% on intraocular pressure spikes following 360° argon laser trabeculoplasty. Ophthalmic Surg Lasers 1995;26:404-9.
49. Munk SA, Wiese A, Thompson CD, MacDonald T. Oxidation potential and allergic response of a2 agonists. Invest Ophthalmol Vis Sci 1996;37(suppl):832.
50. Ashton H, Rawlins MD. Central nervous system depressant actions of clonidine and UK-14,304: partial dissociation of EEG and behavioral effects. Br J Clin Pharmacol 1978;5:135-40.
51. Maier C, Steinberg GK, Sun GH, et al. Neuroprotection by the alpha-2 adrenoceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993;79:306-12.
52. 2-adrenoceptor agonists AGN 191103 and brimonidine. Invest Ophthalmol Vis Sci 1996;37(suppl):114.